Stock comparison
Microsoft
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MSFT
Microsoft
Market cap
$3.13T
Sector
Technology
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MSFT | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 64C | Tie |
| Benjamin Graham | 60C | 67B |
Side-by-side metrics
| Metric | MSFT | RMD |
|---|---|---|
| Market cap | $3.13T | $29.57B |
| P/E (TTM) | 25.0x | 19.6x |
| EV/EBIT | 24.6x | 17.1x |
| ROIC (TTM) | 21.31% | 19.63% |
| Gross margin | 68.31% | 61.69% |
| Net margin | 39.34% | 27.44% |
| Revenue CAGR 5y | 13.78% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MSFT leads on
- Market cap$3.13Tvs $29.57B+99%
- Net margin39.34%vs 27.44%+30%
- Gross margin68.31%vs 61.69%+10%
- Revenue CAGR 5y13.78%vs 12.64%
More like RMD
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.